

NYBCe RESEARCHER PROFILE



ASIM DEBNATH, PhD

Head, Laboratory of Molecular Modeling and Drug Design

LinkedIn: [@asim0debnath-59134755/](https://www.linkedin.com/in/asim0debnath-59134755/)

BACKGROUND

Degree Institution

- Jadavpur University - PhD (Medicinal Chemistry)

Postdoctoral Institution

- Pomona College

AREAS OF RESEARCH

- Drug Discovery Design
- Virology

NYBCe LAB DESCRIPTION

Laboratory of Molecular Modeling and Drug Design: the lab's research focus is to identify new antiviral drugs by state-of-the-art drug design methods.

KEY NON-EXPIRED AWARDED PATENTS

PCT/US2020/061239 - Substituted Heterocyclics With Therapeutic Activity In HIV - Pending

KEY PUBLICATIONS



CONTACT

To contact the lab, email Dr. Debnath at ADebnath@nybc.org or the Office of Sponsored Programs at researchadmin@nybc.org.

To learn more about NYBCe patents and licensing, visit our webpage: <https://www.nybce.org/our-research/nybce-technology-discoveries/>.

INDUSTRY & ACADEMIC PARTNER COLLABORATIONS

- AVIDD Center: Collaborator
- NCI: Collaborator
- Current Computer-Aided Drug Design; International Journal of Quantitative Structure-Property Relationship; International Journal of Molecular Sciences: Editorial Board Member
- American Chemical Society; American Association for the Advancement of Science: Affiliate

COLLABORATIONS OF INTEREST

- Collaborators interested in drug discovery design and protein modelling, particularly for antiviral drugs.

ONGOING PROJECTS

- Identification of small molecule entry inhibitors that specifically target HIV-1 envelope glycoprotein gp120 and disrupt its binding to the T-cell surface receptor CD4.
- Identification of the best combination of latency-reversing agents (LRAs) to facilitate the eradication of HIV-1 from virus reservoirs by drugs, antibody-drug conjugates (ADC), or the immune system. This is expected to help in achieving a functional cure for HIV-1.
- Development of small-molecule pancoronavirus inhibitors to fight against any future coronavirus-related pandemics.
- Development of small-molecule Zika virus entry and NS2B-NS3 protease inhibitor. This project is part of NIAID funded Midwest AVIDD project.

